Doreen Kunze

Summary

Country: Germany

Publications

  1. ncbi request reprint Functional analyses of C13orf19/P38IP in prostate cell lines
    Doreen Kunze
    Department of Urology, Technical University Dresden, Fetscherstrasse 74, D 01307 Dresden, Germany
    Oncol Rep 15:1599-604. 2006
  2. pmc Simultaneous siRNA-mediated knockdown of antiapoptotic BCL2, Bcl-xL, XIAP and survivin in bladder cancer cells
    Doreen Kunze
    Department of Urology, University Hospital Carl Gustav Carus, Technical University of Dresden, D 01307 Dresden, Germany
    Int J Oncol 41:1271-7. 2012
  3. pmc Enhanced inhibition of bladder cancer cell growth by simultaneous knockdown of antiapoptotic Bcl-xL and survivin in combination with chemotherapy
    Doreen Kunze
    Department of Urology, University Hospital Carl Gustav Carus, Technische Universitat Dresden, Fetscherstrasse 74, 01307 Dresden, Germany
    Int J Mol Sci 14:12297-312. 2013
  4. ncbi request reprint siRNA-mediated inhibition of antiapoptotic genes enhances chemotherapy efficacy in bladder cancer cells
    Doreen Kunze
    Department of Urology, University Hospital Carl Gustav Carus, Technical University of Dresden, Fetscherstrasse 74, D 01307 Dresden, Germany
    Anticancer Res 32:4313-8. 2012
  5. ncbi request reprint [In vitro and in vivo evaluation of inhibitory nucleic acid constructs for specific therapy of human urinary bladder carcinoma]
    D Kunze
    Klinik für Urologie, Medizinische Fakultat, Technische Universitat Dresden, Fetscherstrasse 74, 01307 Dresden
    Urologe A 46:1289. 2007
  6. ncbi request reprint Antisense-mediated inhibition of survivin, hTERT and VEGF in bladder cancer cells in vitro and in vivo
    Doreen Kunze
    Department of Urology, Faculty of Medicine, Technical University of Dresden, 01307 Dresden, Germany
    Int J Oncol 32:1049-56. 2008
  7. ncbi request reprint Multitarget siRNA inhibition of antiapoptotic genes (XIAP, BCL2, BCL-X(L)) in bladder cancer cells
    Doreen Kunze
    Department of Urology, Technical University of Dresden, Fetscherstrasse 74, D 01307 Dresden, Germany
    Anticancer Res 28:2259-63. 2008
  8. ncbi request reprint Synthetic nucleic acids as potential therapeutic tools for treatment of bladder carcinoma
    Susanne Fuessel
    Department of Urology, Technical University of Dresden, Dresden, Germany
    Eur Urol 51:315-26; discussion 326-7. 2007
  9. doi request reprint Carbon nanotubes filled with a chemotherapeutic agent: a nanocarrier mediates inhibition of tumor cell growth
    Silke Hampel
    Leibniz Institute for Solid State and Materials Research Dresden, PF 270116, 01171 Dresden, Germany
    Nanomedicine (Lond) 3:175-82. 2008

Detail Information

Publications9

  1. ncbi request reprint Functional analyses of C13orf19/P38IP in prostate cell lines
    Doreen Kunze
    Department of Urology, Technical University Dresden, Fetscherstrasse 74, D 01307 Dresden, Germany
    Oncol Rep 15:1599-604. 2006
    ..No interaction between C13orf19 and p38MAPK was identified. Therefore, the gene should forthwith be named C13orf19 or Fam48A and not P38IP...
  2. pmc Simultaneous siRNA-mediated knockdown of antiapoptotic BCL2, Bcl-xL, XIAP and survivin in bladder cancer cells
    Doreen Kunze
    Department of Urology, University Hospital Carl Gustav Carus, Technical University of Dresden, D 01307 Dresden, Germany
    Int J Oncol 41:1271-7. 2012
    ..5-fold enhancement in apoptosis rate and reduced cellular viability by 40%. Therefore, simultaneous knockdown of antiapoptotic BCL2, Bcl‑xL, XIAP and survivin may represent a promising treatment option for bladder cancer...
  3. pmc Enhanced inhibition of bladder cancer cell growth by simultaneous knockdown of antiapoptotic Bcl-xL and survivin in combination with chemotherapy
    Doreen Kunze
    Department of Urology, University Hospital Carl Gustav Carus, Technische Universitat Dresden, Fetscherstrasse 74, 01307 Dresden, Germany
    Int J Mol Sci 14:12297-312. 2013
    ....
  4. ncbi request reprint siRNA-mediated inhibition of antiapoptotic genes enhances chemotherapy efficacy in bladder cancer cells
    Doreen Kunze
    Department of Urology, University Hospital Carl Gustav Carus, Technical University of Dresden, Fetscherstrasse 74, D 01307 Dresden, Germany
    Anticancer Res 32:4313-8. 2012
    ..Therefore, the knockdown of these four genes could sensitise bladder cancer (BCa) cells towards chemotherapy...
  5. ncbi request reprint [In vitro and in vivo evaluation of inhibitory nucleic acid constructs for specific therapy of human urinary bladder carcinoma]
    D Kunze
    Klinik für Urologie, Medizinische Fakultat, Technische Universitat Dresden, Fetscherstrasse 74, 01307 Dresden
    Urologe A 46:1289. 2007
  6. ncbi request reprint Antisense-mediated inhibition of survivin, hTERT and VEGF in bladder cancer cells in vitro and in vivo
    Doreen Kunze
    Department of Urology, Faculty of Medicine, Technical University of Dresden, 01307 Dresden, Germany
    Int J Oncol 32:1049-56. 2008
    ..In vivo studies with 9 consecutive intraperitoneal injections with 20 mg/kg AS-ODNs or 4.6 mg/kg siRNAs revealed the biocompatibility of both antisense inhibitor types and showed anti-tumoural activity of the AS-ODNs used...
  7. ncbi request reprint Multitarget siRNA inhibition of antiapoptotic genes (XIAP, BCL2, BCL-X(L)) in bladder cancer cells
    Doreen Kunze
    Department of Urology, Technical University of Dresden, Fetscherstrasse 74, D 01307 Dresden, Germany
    Anticancer Res 28:2259-63. 2008
    ..The knockdown of XIAP, BCL2 and BCL-X(L) by siRNAs represents a promising treatment option for bladder cancer (BCa) since the overexpression of antiapoptotic genes is often associated with tumor progression and treatment resistance...
  8. ncbi request reprint Synthetic nucleic acids as potential therapeutic tools for treatment of bladder carcinoma
    Susanne Fuessel
    Department of Urology, Technical University of Dresden, Dresden, Germany
    Eur Urol 51:315-26; discussion 326-7. 2007
    ..Therefore, silencing of abnormally activated genes appears to be a rational approach for specific target-directed and sensitising therapies...
  9. doi request reprint Carbon nanotubes filled with a chemotherapeutic agent: a nanocarrier mediates inhibition of tumor cell growth
    Silke Hampel
    Leibniz Institute for Solid State and Materials Research Dresden, PF 270116, 01171 Dresden, Germany
    Nanomedicine (Lond) 3:175-82. 2008
    ..The drug was introduced into CNTs to demonstrate that they are suited as nanocontainers and nanocarriers and can release the drug to initialize its medical virtue...